Suzanne L. Topalian, MD
Bloomberg-Kimmel Professor of Cancer Immunotherapy
Professor, Surgery and Oncology, Johns Hopkins University School of Medicine
Director, Melanoma Program, Kimmel Cancer Center
Associate Director, Bloomberg-Kimmel Institute for Cancer Immunotherapy
Dr. Topalian is a Professor of Surgery and Oncology at the Johns Hopkins University School of Medicine. She is the director of the Melanoma Program in the Sidney Kimmel Comprehensive Cancer Center, and is an associate director of the Bloomberg~Kimmel Institute for Cancer Immunotherapy at Johns Hopkins.
Dr. Topalian is a physician-scientist whose studies of anti-tumor immunity have been foundational in developing cancer immunotherapy. She received her medical and scientific training at Tufts University School of Medicine, Thomas Jefferson University Hospital, and the National Cancer Institute. She joined the Johns Hopkins Kimmel Cancer Center in 2006 as the inaugural director of its Melanoma Program. Her current research focuses on manipulating “immune checkpoints” such as PD-1 in cancer therapy, discovering biomarkers predicting response and resistance, and developing effective treatment combinations. Dr. Topalian’s work is widely recognized: she was named one of Nature’s 10 in 2014, and received the Karnofsky Award from ASCO in 2015, the Taubman Prize in 2016, and the NCI’s Rosalind E. Franklin Award in 2018, for landmark discoveries in cancer immunotherapy. Dr. Topalian was elected to the National Academy of Medicine in 2017. Her work has opened new avenues of scientific investigation and has established immunotherapy as a pillar of oncology.